0.00Open0.00Pre Close0 Volume0 Open Interest22.50Strike Price0.00Turnover131.63%IV-74.83%PremiumDec 20, 2024Expiry Date9.63Intrinsic Value100Multiplier31DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9014Delta0.0385Gamma1.31Leverage Ratio-0.0120Theta-0.0111Rho-1.18Eff Leverage0.0065Vega
AxoGen Stock Discussion
loading...
looks like more 💰flow and narrower loss this years looks interesting here
In reaction to earnings/guidance:
• $Silvergate Capital (SI.US)$ +10.7% (Silvergate (ticker: SI) notched net income of $38.6 million in the June quarter, delivering earnings per share (EPS) of $1.13.)
• $AxoGen (AXGN.US)$ +3.3% (guides Q2 revs above consensus; also makes changes to its commercial organization),
• $Novartis AG (NVS.US)$ + 3% (The Swiss pharmaceutical company on Tuesday posted net profit of $1.69 billion, down from...
• $Intercept Pharmaceuticals (ICPT.US)$ +25.7% (to sell license to commercialize Ocaliva outside the US to Advanz Pharma for upfront payment of $405 mln)
• $Albemarle (ALB.US)$ +13.9% (earnings reports)
• $Booking Holdings (BKNG.US)$ +10% (Booking Holdings' Outlook for a 'Busy' summer season drives the stock sharply higher)
• $AxoGen (AXGN.US)$ +9% (reports top-line results from RECON study of Avance Nerge Graft)
• $Cumulus Media (CMLS.US)$ +7.2% (an...
No comment yet